Business
Sernova Announces Presentation of HemAcure Hemophilia Program Results at 23rd Annual Meeting of the American Society of Gene and Cell Therapy
(via TheNewswire) L ondon, Ontario - TheNewswire - May 12, 2020 - S...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Announces Presentation of HemAcure Hemophilia Program Results at 23rd Annual Meeting of the American Society of Gene and Cell Therapy(via TheNewswire)\n \n \nLondon, Ontario - TheNewswire - May 12, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, is pleased to announce that the Horizon 2020 HemAcure Consortium will present scientific results of the consortium's research in an abstract entitled Combined Gene and Cell Therapy for the Treatment of Hemophilia A within an Implantable Therapeutic Device in an oral presentation during the ASGCT 23rd Annual Meeting, which is being held in virtual format May 12-15, 2020. The abstract will be presented on May 15 at 11:30 am EDT.\n\n\n \nThe abstract being presented describes scientific results of the HemAcure Consortium's research to develop a novel ex vivo cell-based therapy for the treatment of Hemophilia A using Sernova's Cell Pouch(TM) and paves the way for future clinical testing. Abstract 1359 can be viewed at: https://www.asgct.org/global/documents/abstract-pdf-final-4-30?_zs=S2i4b&_zl=U9052\n\n\n \n\"The Horizon 2020 grant program enabled international experts and innovators in their field, including the Sernova team, to form the HemAcure Consortium to advance the next-generation cell-based regenerative medicine therapy aimed to improve the quality of life for people with hemophilia A. We are excited for members of the HemAcure team to present additional scientific updates at the ASGCT Annual Meeting that further supports Sernova's technologies and their potential in a novel future therapeutic treatment for hemophilia A,\" said Dr. Philip Toleikis, President and CEO of Sernova Corp.\n\n\n \nABOUT HEMACURE\n\n\n \nThe overall objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell-based therapy to treat the bleeding disease, hemophilia A (caused by a genetic deficiency in clotting factor VIII (FVIII)) that should ultimately lead to improved quality of life of the patients. The European Union's Horizon 2020 research and innovation program has awarded approximately EUR5.5 million (CDN$8.5) to support the project. International consortium members include the University Hospital Wurzburg (Coordinating Institute), Germany, IMS - Integrierte Manag...